Catalyst Funds Management’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$290K Sell
48,586
-13,914
-22% -$66K 0.03% 434
2026
Q2
$277K Buy
+62,500
New +$267K 0.02% 513
2024
Q3
– Sell
-2,700
Closed -$15.1K – 1358
2024
Q2
$15.1K Buy
2,700
+2,400
+800% +$14.4K ﹤0.01% 778
2024
Q1
$2.01K Buy
+300
New +$2.37K ﹤0.01% 1052

Other funds holding CTKB

Catalyst Funds Management's CTKB Position: Q3 2026 in Review

Catalyst Funds Management reduced its Cytek Biosciences (CTKB) stake by 22% in Q3 2026, selling an estimated $66K and leaving 48,586 shares worth $290K. The position accounts for 0.03% of the portfolio, ranked #434.

Catalyst Funds Management first reported a position in CTKB in Q1 2024 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Catalyst Funds Management held 48,586 shares of Cytek Biosciences worth $290K as of Q3 2026.
  • Catalyst Funds Management sold 13,914 Cytek Biosciences shares in Q3 2026, an estimated $66K.
  • Cytek Biosciences made up 0.03% of Catalyst Funds Management's portfolio in Q3 2026, its #434 holding.
  • Catalyst Funds Management first reported a position in Cytek Biosciences in Q1 2024 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Catalyst Funds Management's 13F filing for Q3 2026, filed 12 Nov 2026.